Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

OSI Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Advanced Solid Tumors

Treatments: Drug: OSI-7904L; Drug: Cisplatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00116896

OSI-904-102

Details and patient eligibility

About

This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age or older
• Advanced and/or metastatic solid tumor for which no effective therapy is available
• ECOG performance status 0-2
• Adequate bone marrow, hepatic and renal function

Exclusion criteria

• Patients with active or uncontrolled infections
• Neurotoxicity >= Grade 2
• Symptomatic brain metastases which are not stable